
ADAP
Adaptimmune Therapeutics PLC
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.353899
Open
0.3306
VWAP
0.34
Vol
1.11M
Mkt Cap
91.95M
Low
0.330
Amount
376.92K
EV/EBITDA(TTM)
--
Total Shares
255.56M
EV
57.79M
EV/OCF(TTM)
--
P/S(TTM)
0.50
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. The engineered T cell receptor (TCR) platform, which the Company is developing for personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers. It is focused on the commercialization of TECELRA, which is a genetically modified autologous T-cell immunotherapy indicated for the treatment of adults with advanced synovial sarcoma. Its second T-cell immunotherapy, letetresgene autoleucel (lete-cel), targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). It has filed an IND for ADP-5701 for a Phase I trial in Head and Neck Cancer in collaboration with Galapagos NV (Galapagos). It has two pre-clinical programs for the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
17.35M
+438.6%
--
--
14.40M
-64.79%
--
--
11.11M
-91.34%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Adaptimmune Therapeutics plc (ADAP) for FY2025, with the revenue forecasts being adjusted by 27.82% over the past three months. During the same period, the stock price has changed by 25.19%.
Revenue Estimates for FY2025
Revise Upward

+27.82%
In Past 3 Month
Stock Price
Go Up

+25.19%
In Past 3 Month
7 Analyst Rating

300.69% Upside
Wall Street analysts forecast ADAP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADAP is 1.39 USD with a low forecast of 0.46 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
4 Hold
1 Sell
Hold

300.69% Upside
Current: 0.347

Low
0.46
Averages
1.39
High
3.00

300.69% Upside
Current: 0.347

Low
0.46
Averages
1.39
High
3.00
Mizuho
Outperform -> Neutral
downgrade
$0.50
2025-06-25
Reason
Mizuho
Price Target
$0.50
2025-06-25
downgrade
Outperform -> Neutral
Reason
Mizuho downgraded Adaptimmune to Neutral from Outperform with a 50c price target.
Mizuho
Outperform -> Neutral
downgrade
2025-06-25
Reason
Mizuho
Price Target
2025-06-25
downgrade
Outperform -> Neutral
Reason
Barclays
Peter Lawson
Underweight
downgrade
$1
2025-05-14
Reason
Barclays
Peter Lawson
Price Target
$1
2025-05-14
downgrade
Underweight
Reason
Barclays analyst Peter Lawson lowered the firm's price target on Adaptimmune to 46c from $1 and keeps an Underweight rating on the shares. The company's Q1 product revenue was roughly in line with consensus but it evaluated strategic options ongoing to address its constrained capital position, the analyst tells investors in a research note.
Wells Fargo
Equal Weight
downgrade
$1
2025-05-14
Reason
Wells Fargo
Price Target
$1
2025-05-14
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Adaptimmune to $1 from $1.50 and keeps an Equal Weight rating on the shares. While the Tecelra launch is ramping up, the firm sees balance sheet risk in the near term, absent positive outcomes from the ongoing exploration of strategic options, given the limited cash position and quarterly cash burn.
HC Wainwright & Co.
Arthur He
Strong Buy
Maintains
$3.5 → $3
2025-04-01
Reason
HC Wainwright & Co.
Arthur He
Price Target
$3.5 → $3
2025-04-01
Maintains
Strong Buy
Reason
Guggenheim
Michael Schmidt
Strong Buy
Maintains
$3 → $1.75
2025-03-26
Reason
Guggenheim
Michael Schmidt
Price Target
$3 → $1.75
2025-03-26
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Adaptimmune Therapeutics PLC (ADAP.O) is -1.30, compared to its 5-year average forward P/E of -3.74. For a more detailed relative valuation and DCF analysis to assess Adaptimmune Therapeutics PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-3.74
Current PE
-1.30
Overvalued PE
-0.39
Undervalued PE
-7.08
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.62
Current EV/EBITDA
-0.68
Overvalued EV/EBITDA
8.35
Undervalued EV/EBITDA
-7.12
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
53.28
Current PS
1.33
Overvalued PS
161.24
Undervalued PS
-54.68
Financials
Annual
Quarterly
FY2025Q1
YoY :
+28.30%
7.29M
Total Revenue
FY2025Q1
YoY :
-10.54%
-44.07M
Operating Profit
FY2025Q1
YoY :
-1.89%
-47.58M
Net Income after Tax
FY2025Q1
YoY :
-0.00%
-0.03
EPS - Diluted
FY2025Q1
YoY :
+109.84%
-67.80M
Free Cash Flow
FY2025Q1
YoY :
-12.07%
87.93
Gross Profit Margin - %
FY2025Q1
YoY :
-23.54%
-653.18
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 361.34% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
105.3K
USD
13
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
5.1M
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
3.3M
Volume
Months
6-9
2
22.0M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 361.34% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
105.3K
USD
13
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ADAP News & Events
News
4.0
06-26BenzingaThis Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
7.0
05-13SeekingAlphaAdaptimmune targets $35M–$45M TECELRA sales in 2025 as ATC network nears completion
4.0
04-11Business InsiderAdaptimmune downgraded to Hold from Buy at JonesResearch
Sign Up For More News
People Also Watch

NIU
NIU Technologies
3.850
USD
+3.22%

PBYI
Puma Biotechnology Inc
3.280
USD
-3.53%

AMWL
American Well Corp
8.960
USD
+2.99%

AVD
American Vanguard Corp
3.730
USD
+3.32%

GPMT
Granite Point Mortgage Trust Inc
2.660
USD
+0.76%

HFFG
Hf Foods Group Inc
3.030
USD
0.00%

RCMT
R C M Technologies Inc
25.850
USD
-1.07%

FRAF
Franklin Financial Services Corp
42.580
USD
-0.58%

CFBK
CF Bankshares Inc
23.810
USD
-0.25%

CLEU
China Liberal Education Holdings Ltd
0
USD
+5.34%
FAQ

What is Adaptimmune Therapeutics PLC (ADAP) stock price today?
The current price of ADAP is 0.3469 USD — it has increased 4.51 % in the last trading day.

What is Adaptimmune Therapeutics PLC (ADAP)'s business?

What is the price predicton of ADAP Stock?

What is Adaptimmune Therapeutics PLC (ADAP)'s revenue for the last quarter?

What is Adaptimmune Therapeutics PLC (ADAP)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Adaptimmune Therapeutics PLC (ADAP)'s fundamentals?

How many employees does Adaptimmune Therapeutics PLC (ADAP). have?
